NCT01390337 - A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

AC220

Oral Liquid

DRUG

daunorubicin

Intravenous Infusion

DRUG

cytarabine

Intravenous Infusion

Trial Locations (5)

Memorial-Sloan Kettering Cancer Center, New York

Johns Hopkins Medical Institute, Baltimore

Mayo Clinic Jacksonville, Jacksonville

Northwestern University, Chicago

M.D. Anderson Cancer Center, Houston